Brief: Hansa Biopharma Extends Cash Runway Into 2026
18/04/2024 06:05
April 18 (Reuters) - Hansa Biopharma AB HNSA.ST :
* CASH RUNWAY EXTENDED INTO 2026
* ACHIEVED PRICING AND REIMBURSEMENT IN 75% OF EUROPEAN
KIDNEY
TRANSPLANT MARKET
* EXPECTS TO SEE UTILIZATION IN NEW CENTERS RESULTING IN
ADDITIONAL SALES GROWTH IN 2024
Source text for Eikon: ID:nWkr64kLzw
Further company coverage: HNSA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS